References
- Food and Drug Administration. 21 USC 360 c (a)(1). Classification of devices intended for human use; device classes. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/FDCActChapterVDrugsandDevices/ucm110188.htm (accessed 2010-04-27).
- Food and Drug Administration. Overview of IVD regulation. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IVDRegulatoryAssistance/ucm123682.htm#4b: (accessed 2010-04-27). Within section “Medical devices.”
- Food and Drug Administration. Information on cleared and approved IVDs. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/LabTest/ucm126189.htm (accessed 2010-04-27).
- Food and Drug Administration. Critical Path Initiative. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm
- Food and Drug Administration. Critical Path Initiative. http://www.fda.gov/oc/initiatives/criticalpath/reports/opp_list.pdf (accessed 2010-04-27).
- CLSI, previous NCCLS. Evaluation of the linearity of quantitative measurements procedures: A statistical approach; Approved Guideline NCCLS document EP6-A [ISBN 1-56238-498] Wayne PA USA, 2003.
- Medical Devices Standards Database http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Standards/default.htm (accessed 2010-04-27).
- Clinical and Laboratory Standards Institute (CLSI). www.clsi.org (accessed 2010-04-27).
- Russek-Cohen E, Tezak Z, Philip R, Pastel M (2007) Multivariate assays reporting a composite score. JSM Proceedings CD-Rom, 2007.
- Food and Drug Administration. Preliminary concept paper: Drug-diagnostic co-development concept paper. http://www.fda.gov/downloads/Drugs/ScienceResearch/Research Areas/Pharmacogenetics/UCM116689.pdf (accessed 2010-04-27).
- Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SI. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst 2009;101:1453–63.